Petra Hoppmann

Showing 1-7 of 7 articles

Coronary interventions

Preclinical investigation of neoatherosclerosis in magnesium-based bioresorbable scaffolds versus thick-strut drug-eluting stents

Nicol P, Bulin A, Castellanos M, Stöger M, Obermeier S, Lewerich J, Lenz T, Hoppmann P, Baumgartner C, Fischer J, Steiger K, Haude M, Joner M

December 4, 2020 | 10.4244/EIJ-D-19-00747

Coronary interventions

Enhanced platelet inhibition by clopidogrel and risk of bleeding in patients requiring oral anticoagulation after drug-eluting stent implantation

Goedel A, Fiedler K, Mehilli J, Bernlochner I, von Olshausen G, Mayer K, Schüpke S, Hoppmann P, Sibbing D, Maeng M, Massberg S, Schunkert H, Laugwitz K, Kastrati A, Sarafoff N

October 18, 2019 | 10.4244/EIJ-D-18-00995

Coronary interventions

Sex and long-term outcomes after implantation of the Absorb bioresorbable vascular scaffold for treatment of coronary artery disease

Baquet M, Hoppmann P, Grundmann D, Schmidt W, Kufner S, Theiss H, Brunner S, Wiebe J, Eickhoff M, Jochheim D, Byrne R, Laugwitz K, Schunkert H, Massberg S, Kastrati A, Mehilli J

September 20, 2019 | 10.4244/EIJ-D-18-00603

Coronary interventions

Impact of stent size on angiographic and clinical outcomes after implantation of everolimus-eluting bioresorbable scaffolds in daily practice: insights from the ISAR-ABSORB registry

Wiebe J, Hoppmann P, Kufner S, Harada Y, Colleran R, Michel J, Giacoppo D, Schneider S, Cassese S, Ibrahim T, Schunkert H, Laugwitz K, Kastrati A, Byrne R

June 10, 2016 | 10.4244/EIJY16M05_03

Coronary interventions

Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial

Kufner S, Byrne R, Valeskini M, Schulz S, Ibrahim T, Hoppmann P, Schneider S, Laugwitz K, Schunkert H, Kastrati A

March 18, 2016 | 10.4244/EIJY14M11_02

Coronary interventions

Impact of bivalirudin on post-procedural epicardial blood flow, risk of stent thrombosis and mortality after percutaneous coronary intervention

Fiedler A, Ndrepepa G, Schulz S, Floh S, Hoppmann P, Kufner S, Bernlochner I, Byrne R, Schunkert H, Laugwitz K, Kastrati A

February 12, 2016 | 10.4244/EIJV11I11A249

Rationale and design of a randomised clinical trial comparing vascular closure device and manual compression to achieve haemostasis after diagnostic coronary angiography: the Instrumental Sealing of ARterial puncture site – CLOSURE device versus manual compression (ISAR-CLOSURE) trial

Xhepa E, Byrne R, Schulz S, Helde S, Gewalt S, Cassese S, Linhardt M, Ibrahim T, Mehilli J, Hoppe K, Grupp K, Kufner S, Bottiger C, Hoppmann P, Burgdorf C, Fusaro M, Ott I, Schneider S, Hengstenberg C, Schunkert H, Laugwitz K, Kastrati A

June 20, 2014 | 10.4244/EIJV10I2A33

Latest news

NEW ISSUE

State of the Art on ViV-TAVI; Transseptal Punctures; Endovascular Closure and TF-TAVI; Percutaneous PVL Closure: Long-Term Outcomes; and more

October 20, 2021

STATE OF THE ART

Valve-in-valve TAVI: a practical overview

Giuseppe Tarantini et al.

October 20, 2021

AHEAD OF PRINT

TAVI in younger (<70 years old) patients: the AMTRAC registry

Guy Witberg et al.

October 22, 2021

AHEAD OF PRINT

Impact of LVOT calcification in transfemoral TAVI patients

L. Waldschmidt et al.

Impact of preprocedural biological markers on 10-year mortality in the SYNTAXES trial

Hironori Hara et al.

October 22, 2021

AHEAD OF PRINT

Serum caffeine causes adenosine-induced FFR overestimation

Hideaki Tanaka et al.